<DOC>
	<DOCNO>NCT00052312</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know whether doxorubicin cisplatin effective without paclitaxel treat endometrial cancer . PURPOSE : Randomized phase II trial compare effectiveness combine doxorubicin cisplatin without paclitaxel treat patient locally advance , metastatic , and/or relapse endometrial cancer .</brief_summary>
	<brief_title>Doxorubicin Cisplatin With Without Paclitaxel Treating Patients With Locally Advanced , Metastatic , and/or Relapsed Endometrial Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival patient locally advance , metastatic , and/or relapse endometrial cancer treat doxorubicin cisplatin without paclitaxel . - Compare toxicity regimens patient . - Compare progression-free survival 18 month patient treat regimen . - Compare quality life patient treat regimen . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord performance status ( 0 vs 1 v 2 ) , metastatic disease ( M0 v M1 ) , prior pelvic radiotherapy pelvic recurrence ( yes v ) , participate center . Patients randomize 1 2 treatment arm . - Arm I : Patients receive doxorubicin IV 30 minute , paclitaxel IV 3 hour , cisplatin IV 1 hour day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . - Arm II : Patients receive doxorubicin cisplatin arm I . Quality life assess baseline , course , course 3 6 , every 3 month 2 year , every 6 month 3 year , annually thereafter . In event progressive disease , quality life assess every 3 month . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . In event progressive disease , patient follow every 3 month . PROJECTED ACCRUAL : A total 140 patient accrue study .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm endometrial epithelial carcinoma meeting least 1 follow criterion : Advanced metastatic and/or relapse disease Locally advance inoperable unresectable disease No mixed mesodermal tumor and/or tumor show evidence sarcomatous element Uterine papillary serous carcinoma allow PATIENT CHARACTERISTICS : Age 18 Performance status WHO 02 Life expectancy Not specify Hematopoietic Neutrophil count great 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin great 10 g/dL ( transfusion allow ) Hepatic ALT AST less 2 time upper limit normal ( ULN ) Alkaline phosphatase less 2 time ULN Bilirubin less 1.5 time ULN Renal Creatinine less 1.5 time ULN Creatinine clearance great 50 mL/min Cardiovascular Normal baseline EKG Normal baseline LVEF MUGA echocardiogram patient receive prior anthracyclines Other Able tolerate highdose dexamethasone Must consider fit chemotherapy No uncontrolled infection No malignancy within past 5 year except successfully treat basal cell skin cancer carcinoma situ cervix No prior nervous psychiatric disorder would preclude study compliance No psychological , familial , sociological , geographic condition would preclude study participation Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy At least 12 month since prior adjuvant chemotherapy Total dose prior doxorubicin great 200 mg/m^2 Total dose prior epirubicin great 300 mg/m^2 Endocrine therapy At least 28 day since prior hormonal therapy patient partial complete response firstline treatment Radiotherapy No prior radiotherapy area pelvis No concurrent radiotherapy Surgery Not specify Other No concurrent anticancer medication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>recurrent endometrial carcinoma</keyword>
	<keyword>stage III endometrial carcinoma</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>endometrial papillary serous carcinoma</keyword>
</DOC>